The shares of Alkermes plc (NASDAQ:ALKS) traded with a loss of -0.01 points or -0.02% in the most recent session. The shares last traded at $41.88. As per the trading info, the shares saw $7.47 million in upticks and lost $5.22 million in downticks, resulting in a net money flow of $2.25 million. The up/down ratio for the day was measured at 1.43. For the week, the shares had posted 1.23%.From the block trade data available, the total upticks were valued at $2.4 million and the total downticks were valued at $0 million, thereby putting the up/down ratio at 0. The net money flow for the block transaction was $2.4 million.
The stock has recorded a 20-day Moving Average of 4.94% and the 50-Day Moving Average is 0.75%. The company shares have dropped 37.47% in the past 52 Weeks. On December 29, 2015 The shares registered one year high of $80.71 and one year low was seen on March 17, 2016 at $27.14. The 50-day moving average is $41.95 and the 200 day moving average is recorded at $45.23. S&P 500 has rallied 1.93% during the last 52-weeks.
Alkermes plc (NASDAQ:ALKS): The stock opened at $42.29 on Tuesday but the bulls could not build on the opening and the stock topped out at $42.55 for the day. The stock traded down to $41.27 during the day, due to lack of any buying support eventually closed down at $41.85 with a loss of -0.10% for the day. The stock had closed at $41.89 on the previous day. The total traded volume was 926,055 shares.
Currently the company Insiders own 4.75% of Alkermes plc shares according to the proxy statements. Institutional Investors own 96.65% of Alkermes plc shares. During last six month period, the net percent change held by insiders has seen a change of 6.36%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Mitchell Paul J, director of Alkermes Plc., had unloaded 2,000 shares at an average price of $44.97 in a transaction dated on June 6, 2016. The total value of the transaction was worth $89,940.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.